{"article_id": "ZTS_q1_2021.txt", "article": ["in the first quarter , we grew our top line revenue at 21 % operationally , our best quarter ever , with 25 % operational growth internationally and 19 % growth in the u.s. china and brazil led our international performance with 75 % and 48 % operational growth respectively , exhibiting their strength in both companion animal and livestock product sales .", "in total , our containment animal portfolio grew 34 % operationally based on the strength of our parasiticides and dermatology products , while our livestock portfolio grew 8 % operationally with solid growth in cattle , swine and fish products .", "it is exceeding expectations and has been well received by customers , with a 90 % plus penetration rate in our largest u.s. corporate accounts .", "after several successful innovations in the last few years , these products made up 16 % of our total sales in the first quarter and includes such brands as simparica , simparica trio , revolution , stronghold and proheart .", "in the containment animal space , we 've also continued to be pleased with our diagnostics portfolio , which grew 47 % operationally in the first quarter .", "looking ahead , we are raising guidance for operational growth and full year revenue to the range of 10.5 % to 12 % .", "we 've built a comprehensive and rigorous approach through our driven to care program , and our goals include support for 10 of the 17 united nations sustainable development goals .", "in 2014 , our companion animal business was 34 % of our total revenue .", "last year , it had grown to 55 % based on the strength of our innovation and investment in growth , and we see that continuing to expand .", "in the first quarter , we generated revenue of $ 1.9 billion , growing 22 % on a reported basis and 21 % operationally .", "adjusted net income of $ 603 million with an increase of 33 % on a reported basis and 34 % operationally .", "operational revenue grew 21 % , resulting entirely from volume increases with price flat for the quarter .", "volume growth of 21 % includes 13 % from other in line products , 5 % from new products , and 3 % from key dermatology products .", "companion animal products led the way in terms of species growth , growing 34 % operationally , with livestock growing 8 % operationally in the quarter .", "following blockbuster sales in year one , simparica trio began 2021 with strong first quarter performance , posting revenue of $ 90 million , growing sequentially each quarter since launch .", "u.s. market share within the flea , tick and heartworm segment is now at an all - time high of 31 % , representing an increase of more than 9 % for the first quarter versus the same period in the prior year .", "global sales of our key dermatology portfolio were $ 245 million in the quarter , growing 24 % operationally .", "we remain confident that key dermatology sales will exceed $ 1 billion this year .", "our diagnostics portfolio grew 47 % in q1 , led by increases in consumable and instrument revenue .", "our swine portfolio grew 19 % operationally as large producers continued rebuilding herds as they recover from african swine fever and created significant demand for our products .", "u.s. revenue grew 19 % , with companion animal products growing 32 % and livestock sales declining by 4 % .", "while severe weather caused a slight decline in vet clinic traffic for the quarter , revenue per visit was up more than 10 % .", "our small animal parasiticide portfolio was the largest contributor to companion animal growth , growing 74 % in the quarter .", "simparica trio continues to perform well in the u.s. with sales of $ 83 million .", "the simparica franchise generated sales of $ 112 million in the quarter and is now the number 2 brand in the u.s. flea , tick and heartworm segment .", "companion animal diagnostic sales increased 62 % in the quarter as the continued recovery at the vet clinic and a favorable prior year comparative period led to significant growth in point - of - care consumable revenue .", "key dermatology sales were $ 157 million for the quarter , growing 16 % with significant growth for apoquel and cytopoint .", "u.s. livestock declined 4 % in the quarter , driven primarily by poultry as producers switching to lower - cost alternatives unfavorably impacted our business .", "cattle grew 6 % in the quarter as promotional programs and the timing of generic entrants drove growth across the product portfolio .", "revenue in our international segment grew 25 % operationally in the quarter , with companion animal revenue growing 37 % operationally and livestock revenue growing 17 % operationally .", "companion animal diagnostics grew 18 % in the quarter , led by a 24 % increase in point - of - care consumable revenue and a second consecutive quarter of double - digit increase in instrument placement revenue .", "swine revenue grew 29 % operationally led by growth in china of 128 % , marking the third consecutive quarter with swine growth in excess of 100 % .", "cattle grew 11 % operationally in the quarter as a result of marketing campaigns , key account penetration , and favorable export market conditions in brazil and several other emerging markets .", "our fish portfolio delivered another strong quarter , growing 39 % operationally driven by strong performance in chile , the timing of seasonal vaccination protocols , and the 2020 acquisition of fish vet group .", "china total sales grew 75 % operationally , which in addition to the significant growth in swine , delivered 59 % operational growth in companion animal .", "brazil grew 48 % operationally in the quarter as sales of simparica , the leading oral parasiticide in the brazilian market , drove a 73 % operational increase in companion animal .", "adjusted gross margin of 71 % increased 70 basis points on a reported basis compared to the prior year as a result of favorable product mix , partially offset by foreign exchange and other costs , including freight .", "adjusted operating expenses increased 8 % operationally , resulting from increased compensation - related costs and advertising and promotion expense for simparica trio .", "the adjusted effective tax rate for the quarter was 19 % , an increase of 230 basis points driven by a reduction in favorable discrete items compared to the prior year 's comparable quarter , partially offset by the favorable impact of the jurisdictional mix of earnings .", "adjusted net income and adjusted diluted earnings per share grew 34 % operationally for the quarter , primarily driven by revenue growth .", "we resumed our share repurchase program in the first quarter , repurchasing approximately $ 180 million worth of shares .", "for revenue , we are raising and narrowing our guidance range , with projected revenue now between $ 7.5 billion and $ 7.625 billion and operational revenue growth between 10.5 % and 12 % for the full year versus the 9 % to 11 % in our february guidance .", "adjusted net income is now expected to be in the range of $ 2.12 billion to $ 2.16 billion , representing operational growth of 12 % to 14 % compared to our prior guidance of 9 % to 12 % .", "adjusted diluted earnings per share is now expected to be in the range of $ 4.42 to $ 4.51 , and reported diluted earnings per share to be in the range of $ 4.08 to $ 4.19 ."], "summary_gold": "sees fy earnings per share $ 4.08 to $ 4.19 .<q>sees fy revenue $ 7.5 billion to $ 7.625 billion .<q>q1 revenue rose 22 percent to $ 1.9 billion .<q>sees fy adjusted earnings per share $ 4.42 to $ 4.51 .", "summary_pred": "adjusted operating expenses increased 8 % operationally , resulting from increased compensation - related costs and advertising and promotion expense for simparica trio .<q>u.s. revenue grew 19 % , with companion animal products growing 32 % and livestock sales declining by 4 % .<q>swine revenue grew 29 % operationally led by growth in china of 128 % , marking the third consecutive quarter with swine growth in excess of 100 % .<q>our fish portfolio delivered another strong quarter , growing 39 % operationally driven by strong performance in chile , the timing of seasonal vaccination protocols , and the 2020 acquisition of fish vet group .<q>companion animal diagnostics grew 18 % in the quarter , led by a 24 % increase in point - of - care consumable revenue and a second consecutive quarter of double - digit increase in instrument placement revenue .<q>for revenue , we are raising and narrowing our guidance range , with projected revenue now between $ 7.5 billion and $ 7.625 billion and operational revenue growth between 10.5 % and 12 % for the full year versus the 9 % to 11 % in our february guidance .<q>we resumed our share repurchase program in the first quarter , repurchasing approximately $ 180 million worth of shares .<q>it is exceeding expectations and has been well received by customers , with a 90 % plus penetration rate in our largest u.s. corporate accounts .<q>we 've built a comprehensive and rigorous approach through our driven to care program , and our goals include support for 10 of the 17 united nations sustainable development goals .<q>volume growth of 21 % includes 13 % from other in line products , 5 % from new products , and 3 % from key dermatology products .<q>adjusted diluted earnings per share is now expected to be in the range of $ 4.42 to $ 4.51 , and reported diluted earnings per share to be in the range of $ 4.08 to $ 4.19 .<q>we remain confident that key dermatology sales will exceed $ 1 billion this year .<q>following blockbuster sales in year one , simparica trio began 2021 with strong first quarter performance , posting revenue of $ 90 million , growing sequentially each quarter since launch .<q>in 2014 , our companion animal business was 34 % of our total revenue .<q>adjusted gross margin of 71 % increased 70 basis points on a reported basis compared to the prior year as a result of favorable product mix , partially offset by foreign exchange and other costs , including freight .<q>operational revenue grew 21 % , resulting entirely from volume increases with price flat for the quarter .", "len_article": 44, "len_summary_gold": 4, "len_summary_pred": 16, "len_sent_scores": 44}